JP2007509903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509903A5 JP2007509903A5 JP2006537243A JP2006537243A JP2007509903A5 JP 2007509903 A5 JP2007509903 A5 JP 2007509903A5 JP 2006537243 A JP2006537243 A JP 2006537243A JP 2006537243 A JP2006537243 A JP 2006537243A JP 2007509903 A5 JP2007509903 A5 JP 2007509903A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- microparticle
- motomeko
- copolymer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011859 microparticle Substances 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 239000010419 fine particle Substances 0.000 claims 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229920003176 water-insoluble polymer Polymers 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229920001480 hydrophilic copolymer Polymers 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 101710149951 Protein Tat Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 238000012674 dispersion polymerization Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
- 230000000379 polymerizing effect Effects 0.000 claims 1
- 239000004926 polymethyl methacrylate Substances 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0325624A GB2407500A (en) | 2003-11-03 | 2003-11-03 | Use of microparticles for antigen delivery |
| PCT/EP2004/012421 WO2005049093A1 (en) | 2003-11-03 | 2004-11-03 | Use of microparticles for antigen delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509903A JP2007509903A (ja) | 2007-04-19 |
| JP2007509903A5 true JP2007509903A5 (enExample) | 2007-11-29 |
Family
ID=29725849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006537243A Withdrawn JP2007509903A (ja) | 2003-11-03 | 2004-11-03 | 抗原送達のための微粒子の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070275071A1 (enExample) |
| EP (1) | EP1696964A1 (enExample) |
| JP (1) | JP2007509903A (enExample) |
| GB (1) | GB2407500A (enExample) |
| WO (1) | WO2005049093A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2259798B1 (en) * | 2008-03-05 | 2013-12-11 | Baxter International Inc. | Surface-modified particles and methods for targeted drug delivery |
| US8323696B2 (en) * | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
| WO2010111292A1 (en) | 2009-03-23 | 2010-09-30 | Nanirx, Inc. | Treatment of cancer with immunostimulatory hiv tat derivative polypeptides |
| US20130101609A1 (en) * | 2010-01-24 | 2013-04-25 | Novartis Ag | Irradiated biodegradable polymer microparticles |
| US9717827B2 (en) * | 2012-09-12 | 2017-08-01 | The Regents Of The University Of California | Immunomodulatory materials for implantable medical devices |
| CA2939581C (en) * | 2014-02-20 | 2024-01-23 | Vaxart, Inc. | Formulations for small intestinal delivery |
| JP2017512499A (ja) * | 2014-03-25 | 2017-05-25 | デューク ユニバーシティ | モザイクｈｉｖ−１配列およびその使用 |
| ES2832504T3 (es) | 2015-06-12 | 2021-06-10 | Vaxart Inc | Formulaciones para administración de antígenos de norovirus y rsv en el intestino delgado |
| WO2019161171A1 (en) * | 2018-02-16 | 2019-08-22 | Sperovie Biosciences, Inc. | Nanoparticle formulations of sting agonists |
| US20220175812A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3174918D1 (en) * | 1980-12-23 | 1986-08-14 | Boehringer Mannheim Gmbh | Hydrophilic latex particles, process for their preparation and their use |
| DE3048883A1 (de) * | 1980-12-23 | 1982-07-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Hydrophile latexpartikel, verfahren zu deren herstellung und deren verwendung |
| FR2596399B1 (fr) * | 1986-03-28 | 1988-09-02 | Univ Rennes | Nanoparticules a base de polymere ou copolymere methacrylique, procede de preparation, et application comme vecteur de medicament |
| US5334394A (en) * | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
| GB9406094D0 (en) * | 1994-03-28 | 1994-05-18 | Univ Nottingham And University | Polymer microspheres and a method of production thereof |
| GB9818591D0 (en) * | 1998-08-27 | 1998-10-21 | Danbiosyst Uk | Pharmaceutical composition |
| DE10118852A1 (de) * | 2001-04-17 | 2002-10-31 | Fricker Gert | Bdellosomen |
| WO2002000191A2 (de) * | 2000-06-29 | 2002-01-03 | Bernina Biosystems Gmbh | Bdellosomen |
| CN101428006A (zh) * | 2000-09-28 | 2009-05-13 | 诺华疫苗和诊断公司 | 微粒体组合物及其生产方法 |
-
2003
- 2003-11-03 GB GB0325624A patent/GB2407500A/en not_active Withdrawn
-
2004
- 2004-11-03 WO PCT/EP2004/012421 patent/WO2005049093A1/en not_active Ceased
- 2004-11-03 EP EP04797558A patent/EP1696964A1/en not_active Withdrawn
- 2004-11-03 JP JP2006537243A patent/JP2007509903A/ja not_active Withdrawn
- 2004-11-03 US US10/577,974 patent/US20070275071A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509902A5 (enExample) | ||
| JP2007509903A5 (enExample) | ||
| Thomas et al. | Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine | |
| Bhavsar et al. | Functionalized and graft copolymers of chitosan and its pharmaceutical applications | |
| Binjawadagi et al. | Adjuvanted poly (lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs | |
| Stano et al. | Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization | |
| KR101799625B1 (ko) | 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물 | |
| CN104027324B (zh) | 一种可溶性微针疫苗贴片及其制备方法 | |
| US10980878B2 (en) | Methods and compositions for modulating Akt3 activity | |
| JP2008522989A5 (enExample) | ||
| CN101484147B (zh) | 对于具有水中良好溶解性的活性成分具有受控的活性成分释放性的药物组合物 | |
| JP2016517425A5 (enExample) | ||
| US10292978B2 (en) | Specific Akt3 inhibitor and uses thereof | |
| JP2014505736A5 (enExample) | ||
| JPS63255230A (ja) | 徐放性製剤 | |
| JP2007197470A5 (enExample) | ||
| CN1044590A (zh) | 持续释放二甲苯氧庚酸组合物的制备方法 | |
| Chen et al. | Molecular evaluation of oral immunogenicity of hepatitis B antigen delivered by hydrogel microparticles | |
| Hani et al. | Current perspectives on novel drug delivery systems and approaches for management of cervical cancer: a comprehensive review | |
| Zhang et al. | Polymer–protein core–shell nanoparticles for enhanced antigen immunogenicity | |
| Bromberg | Intelligent polyelectrolytes and gels in oral drug delivery | |
| CA2597800A1 (en) | Partly neutralized anionic (meth)acrylate copolymer | |
| JP2003511403A5 (enExample) | ||
| Krogstad et al. | Vaginal drug delivery | |
| Roopngam et al. | Hepatitis C virus E2 protein encapsulation into poly d, l-lactic-co-glycolide microspheres could induce mice cytotoxic T-cell response |